Liraglutide Injection, Solution
Product Images NDC 81607-019

Product Visual Gallery

This gallery contains 45 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 81607-019). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Orbicular Pharmaceutical Technologies Private Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 01)

Chemical structure diagram representing the amino acid sequence of liraglutide, including a C-16 fatty acid (palmitoyl) modification. The sequence is depicted as a connected series of circles labeled with amino acid abbreviations.*

FDA Label Image

Figure 2 (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 02)

Two cumulative frequency charts comparing percentage change in body weight for liraglutide injection versus placebo. The left chart shows a range from -30% to +20%, the right chart ranges from -10% to +20%, both with cumulative frequency percentages on the vertical axis. Liraglutide injection shows higher frequency of greater weight loss compared to placebo in both charts.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 03)

Two line graphs compare percentage change in body weight over 56 weeks between liraglutide injection and placebo groups. The graphs show a greater body weight reduction over time with liraglutide injection versus placebo in studies with different patient populations, with data points labeled for weeks and number of patients completing visits.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 04)

A line graph comparing percentage change in body weight over weeks between liraglutide injection and placebo groups. The x-axis shows weeks from baseline through approximately 56 weeks, and the y-axis shows body weight change percentage. The liraglutide group shows a greater decline in body weight over time compared to the placebo group, with measured values indicated at several time points.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 05)

A line graph showing mean changes from baseline in BMI SDS (Body mass index standard deviation score) over weeks since randomisation for liraglutide 3.0 mg injection and placebo groups. The graph includes error bars for standard error of the mean and sample sizes for both groups across multiple weeks.*

FDA Label Image

Example Diagram (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 06)

Illustration of a liraglutide injection pen and needle components showing the pen cap, pen scale and window, dose counter, dose pointer, dose selector, and dose button. Separate parts of the needle include the outer needle cap, inner needle cap, needle, and paper tab. An inset highlights the flow check symbol on the pen's dose selector.*

FDA Label Image

3spackcarton (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 07)

Packaging label for Liraglutide Injection 18 mg/3 mL (6 mg/mL) by Orbicular Pharmaceutical Technologies Private Limited. The label describes the product as a 5 x 3 mL prefilled pen subcutaneous injection, includes usage instructions, storage conditions, and manufacturer information. The label features images of the pen and a needle, a barcode, and the NDC 81607-019-02.*

FDA Label Image

5spackcarton (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 08)

Liraglutide Injection 18 mg/3 mL (6 mg/mL) subcutaneous injection solution in a package containing 3 prefilled 3 mL pens. The label includes directions for use, storage instructions to refrigerate without freezing, and warnings to protect from light. Manufacturer is Orbicular Pharmaceutical Technologies Private Limited. The packaging also features a barcode and batch coding area.*

FDA Label Image

Label (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 09)

Label for liraglutide injection 18 mg/3 mL (6 mg/mL) subcutaneous solution, produced by Orbicular Pharmaceutical Technologies Private Limited. The label includes dosing details, storage instructions to refrigerate before first use, and notes single patient use. NDC 81607-019-03 is visible along with a barcode and manufacturer information indicating the product is made in India.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 10)

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 11)

An instructional diagram showing a hand holding a small injection device with a flow check symbol selected. A close-up inset details the flow check window on the device. The illustration likely relates to the use of liraglutide injection solution for subcutaneous administration.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 12)

A carton for liraglutide injection, solution, with a strength of 6 mg/mL. The label prominently displays the proprietary name liraglutide along with the dosage form "Injection, Solution". The package includes the manufacturer name, Orbicular Pharmaceutical Technologies Private Limited, and the National Drug Code (NDC) 81607-019. The box shows a secure-looking, primarily white and silver design with printed text detailing product and regulatory information.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 13)

liraglutide 6 mg/mL injection, solution in a prefilled injection pen by Orbicular Pharmaceutical Technologies Private Limited. The label on the pen is predominantly white, featuring dosage and administration details along with the brand and generic names.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 14)

An instructional illustration showing a hand holding a liraglutide injection pen, demonstrating the step of pulling down a white part at the bottom of the pen, indicated by an upward arrow. An inset image highlights the top of the pen, focusing on the cap removal or preparation step.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 15)

Liraglutide 6 mg/mL injection, solution in a 3 mL single-use prefilled pen. The packaging shows the product name, strength, dosage form, route (subcutaneous), manufacturer Orbicular Pharmaceutical Technologies Private Limited, and the NDC 81607-019.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 16)

The label of liraglutide injection, solution with a strength of 6 mg/mL, designed for subcutaneous administration. The product is labeled by Orbicular Pharmaceutical Technologies Private Limited and includes a clear layout showing the brand and generic name 'liraglutide' prominently.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 17)

An instructional illustration depicting the selection of a 0.6 mg dose on a liraglutide injection pen. The image shows a hand turning the dose selector on the pen to the 0.6 mg mark, with text indicating "0.6 mg selected" as an example.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 18)

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 19)

An instructional diagram showing a partially used injection pen for liraglutide 6 mg/mL solution. The pen displays dose markings at 0.6 mg, 3 mg, and 6 mg, with an annotation indicating "Approx. 3 mg left." The image is labeled as an example to illustrate dose measurement or remaining medication.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 2)

An instructional diagram illustrating a step in handling a prefilled injection device for liraglutide 6 mg/mL solution. The image shows two hands holding the injection pen, with an arrow indicating twisting or pulling action likely related to removing the cap or preparing the device for use.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 20)

liraglutide 6 mg/mL injection, solution in a vial. The label shows the product name liraglutide, strength 6 mg/mL, for subcutaneous use, and the manufacturer Orbicular Pharmaceutical Technologies Private Limited. The vial has a clear glass body with a blue and white label and a blue cap.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 21)

liraglutide 6 mg/mL injection, solution in a vial, labeled for subcutaneous use. The vial is dark-colored with a black cap and displays the product name 'liraglutide' prominently on the label. The label includes dosage strength and volume details, along with the labeler Orbicular Pharmaceutical Technologies Private Limited. The vial is vertically oriented in the image.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 22)

An instructional illustration showing a cartridge-style injection device with a dose counter and a purple cap. The top part depicts a hand lifting the cap. The bottom shows a close-up of the dose counter displaying 2.4 mg. Text below reads "Example Dose counter stopped: 2.4 mg left." This likely demonstrates how to view or interpret the remaining dose on the device.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 23)

Illustration showing a hand holding a liraglutide injection pen with an arrow pointing downward, indicating the injection technique or direction for subcutaneous administration.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 24)

An instructional diagram showing a hand holding a liraglutide injection pen with a blue arrow indicating downward pressure. An inset highlights the dose window displaying "0 mg," suggesting dose adjustment or needle injection process for the subcutaneous solution injection form.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 25)

An instructional illustration showing a hand holding a liraglutide injection pen, with a speech bubble instructing to count slowly from 1 to 6. The background includes a label 'N' in a blue square at the top left corner.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 26)

The packaging label for liraglutide 6 mg/mL injection, solution, for subcutaneous use. The container is a clear glass vial with a metal cap and a red flip-off seal. The label includes the proprietary name liraglutide, strength, dosage form, and NDC number 81607-019, with Orbicular Pharmaceutical Technologies Private Limited as the labeler. The vial contains 3 mL of solution.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 27)

An instructional illustration showing two steps for using a liraglutide injection pen. Step 1 depicts removing the pen cap, and step 2 illustrates screwing a new needle onto the pen. The figures use simple hand outlines to demonstrate these actions.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 28)

Illustration showing a subcutaneous injection device with a needle pointing downward and a blue arrow indicating an upward direction. The device is marked with dosage increments from 1 to 10.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 29)

An instructional illustration showing how to attach a needle to a liraglutide injection pen. The image depicts a hand twisting the needle onto the pen device, labeled with the step 'Needle' and marked with the letter P.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 3)

Illustration showing a close-up view of a hand holding a liraglutide injection pen, focusing on the dosage window of the pen where the amount to be injected is measured. The image highlights the proper way to hold the liraglutide subcutaneous injection pen for dose preparation.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 30)

Illustration showing the process of adding a liquid from a vial top into a container or device. The image includes an arrow indicating the direction of the liquid flow from the vial cap to the container below, emphasizing a step in the medication preparation or administration process.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 31)

An instructional illustration showing hands assembling or preparing a liraglutide injection device, focusing on connecting parts in a subcutaneous injection pen marked with an "R".*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 32)

Liraglutide 6 mg/mL injection, solution in a subcutaneous dosage form, packaged in a multi-dose vial. The label shows the product name liraglutide, strength of 6 mg/mL, and the labeler Orbicular Pharmaceutical Technologies Private Limited. The vial is clear with a purple-tinted cap and contains identification and usage instructions in small text.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 33)

Liraglutide 6 mg/mL injection, solution for subcutaneous use, in a single-dose carton labeled with product information including active ingredient, strength, and manufacturer Orbicular Pharmaceutical Technologies Private Limited. The packaging indicates a 3 mL volume and includes branding and usage instructions.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 34)

The packaging label for liraglutide injection, solution 6 mg/mL, by Orbicular Pharmaceutical Technologies Private Limited. The carton displays the product name "liraglutide (liraglutide) Injection, 6 mg/mL" with dosage form information and includes a visual depiction of the product's vial. Container details such as volume or count are not visible in the image.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 35)

Illustration diagram depicting the connection of an injection pen needle to the pen device, with arrows indicating the direction to attach the needle. The image includes a label 'S' in the upper-left corner and shows a hand positioning the needle for subcutaneous injection preparation.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 36)

liraglutide 6 mg/mL injection solution for subcutaneous use in a 3 mL single-dose prefilled pen cartridge. The packaging box and pen cartridge are labeled with the proprietary name liraglutide and indicate the strength as 6 mg/mL. The labeler is Orbicular Pharmaceutical Technologies Private Limited.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 4)

An instructional illustration showing a hand holding a syringe-like pen device with a needle cover. A blue arrow points to the needle cover being pulled off or manipulated, suggesting a step in preparing the injection device for use.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 5)

An instructional illustration showing a hand pressing the cap of a syringe-type injection device, labeled with a letter 'D' in the top left corner. The image highlights the step of preparing the injection device, possibly indicating the removal or pressing of the cap before use.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 6)

An instructional illustration showing a hand attaching a needle to a liraglutide injection pen. The diagram focuses on securing the needle to the pen device, indicated by a blue arrow pointing towards the needle attachment point.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 7)

The cardboard carton for liraglutide 6 mg/mL subcutaneous injection by Orbicular Pharmaceutical Technologies Private Limited. The box is primarily white with blue and light blue decorative elements. It includes the product name "liraglutide" prominently on the front along with some text in a smaller font that likely contains usage or manufacturing information.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 8)

liraglutide 6 mg/mL injection, solution in a vial with label by Orbicular Pharmaceutical Technologies Private Limited. The label shows the product name liraglutide, strength 6 mg/mL, dosage form injection for subcutaneous use, and a lot number with expiration date on the vial.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 142 9)

An instructional illustration showing a hand holding a small rubber stopper or cap, preparing to remove or attach it to the tip of a pen-style injectable device, indicated by an arrow. This diagram appears to guide the user on preparing a liraglutide injection pen for use.*

FDA Label Image

Image (4f67d1f2 0158 4758 Ae02 0cd65eaaae14 186 1)

Liraglutide 6 mg/mL injection, solution in a subcutaneous injectable vial. The label includes the proprietary and generic name liraglutide, dosage form, and strength. The manufacturer is Orbicular Pharmaceutical Technologies Private Limited. The vial label also shows product and manufacturing details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.